<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00245115</url>
  </required_header>
  <id_info>
    <org_study_id>J0563 CDR0000453619</org_study_id>
    <secondary_id>P01CA070970</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <nct_id>NCT00245115</nct_id>
    <nct_alias>NCT00246649</nct_alias>
  </id_info>
  <brief_title>Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia</brief_title>
  <official_title>Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs,&#xD;
      helps stem cells move from the bone marrow to the blood so they can be collected. Treating&#xD;
      stem cells collected from the patient's blood or bone marrow with chemotherapy in the&#xD;
      laboratory removes any remaining cancer cells. Chemotherapy or radiation therapy is given to&#xD;
      the patient to prepare the bone marrow for stem cell transplant. The treated stem cells are&#xD;
      then returned to the patient to replace the blood-forming cells that were destroyed by the&#xD;
      chemotherapy.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well an autologous peripheral stem cell or bone&#xD;
      marrow transplant using laboratory-treated cells works in treating patients with acute&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of ex vivo expanded mafosfamide-purged CD34-positive cells for&#xD;
           autologous peripheral blood stem cell or bone marrow transplantation in patients with&#xD;
           acute leukemia.&#xD;
&#xD;
        -  Determine the duration of aplasia associated with the use of ex vivo cytokine expanded&#xD;
           mafosfamide-purged cells in patients treated with this regimen.&#xD;
&#xD;
        -  Determine, preliminarily, the event-free survival of patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
        -  Mobilization and stem cell collection: Patients receive cyclophosphamide IV and&#xD;
           filgrastim (G-CSF) subcutaneously (SC) or IV once daily for 7-14 days followed by&#xD;
           leukapheresis to collect peripheral blood stem cells (PBSCs). Some patients may also&#xD;
           undergo bone marrow (BM) harvest if sufficient PBSCs are not collected. Patients with a&#xD;
           sufficient number of stem cells or BM (5 x 10^6 PBSC/kg or 3 x 10^8 BM cells/kg) proceed&#xD;
           to autologous PBSC transplantation (PBSCT) or BM transplantation (BMT).&#xD;
&#xD;
        -  CD34-positive cell selection and mafosfamide purging: Collected PBSCs and/or BM are&#xD;
           treated in the laboratory to isolate CD34-positive cells. A minimum of 1 x 10^6&#xD;
           nucleated CD34-positive BM cells/kg or 2 x 10^6 nucleated CD34-positive PBSCs/kg must be&#xD;
           available after selection to proceed to mafosfamide-purging. The selected cells are then&#xD;
           treated in vitro with mafosfamide to purge remaining leukemic cells. One third of the&#xD;
           mafosfamide-purged cells are then cryopreserved for future use and 2/3 of the&#xD;
           mafosfamide-purged cells proceed to ex vivo expansion.&#xD;
&#xD;
        -  Ex vivo expansion: The remaining CD34-positive mafosfamide-purged cells are treated in&#xD;
           vitro with stem cell factor, G-CSF, and recombinant human thrombopoietin and incubated&#xD;
           for 12-14 days.&#xD;
&#xD;
        -  Myeloablative therapy: Patients receive busulfan on days -9 to -6 and cyclophosphamide&#xD;
           on days -5 to -2.&#xD;
&#xD;
        -  PBSCT or BMT: Patients undergo autologous PBSCT or BMT using CD34-positive&#xD;
           mafosfamide-purged cryopreserved cells and ex vivo expanded CD34-positive&#xD;
           mafosfamide-purged cells on day 0 followed by G-CSF SC or IV once daily until blood&#xD;
           counts recover.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Expiration of study supply&#xD;
  </why_stopped>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients infused with Mf-treated cells with successful expansion</measure>
    <time_frame>2 weeks</time_frame>
    <description>Number of patients with successful expansion of a CD34 selected, mafosfamide purged autograft.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of aplasia as determined by Number of Days to Absolute Neutrophil Count (ANC) recovery</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">7</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of acute leukemia meeting 1 of the following criteria:&#xD;
&#xD;
               -  High-risk acute myeloid leukemia (AML) in first complete remission (CR) with no&#xD;
                  matched family donor available, including any of the following types:&#xD;
&#xD;
                    -  Secondary AML&#xD;
&#xD;
                    -  AML with chromosome 5 or 7 abnormalities&#xD;
&#xD;
                    -  AML with trisomy 8&#xD;
&#xD;
                    -  AML with 6;9 chromosomal translocation&#xD;
&#xD;
                    -  AML with 11q23 chromosomal abnormality&#xD;
&#xD;
                    -  AML with multiple or complex chromosomal abnormalities&#xD;
&#xD;
                    -  AML with FAB M6 or M7&#xD;
&#xD;
               -  AML in second CR (CR2) with no eligible HLA-identical sibling donor available&#xD;
&#xD;
               -  High-risk acute lymphoblastic leukemia (ALL) with no eligible HLA-identical&#xD;
                  sibling donor available, including any of the following types:&#xD;
&#xD;
                    -  Philadelphia chromosome-positive ALL&#xD;
&#xD;
                    -  ALL with 11q23 chromosomal abnormality&#xD;
&#xD;
                    -  ALL in CR2&#xD;
&#xD;
          -  Eligible for and willing to undergo bone marrow transplantation&#xD;
&#xD;
          -  No intermediate- or good-risk acute leukemia in CR1&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Availability of a suitable matched HLA-identical sibling marrow donor&#xD;
&#xD;
          -  Intermediate or good risk acute leukemia in CR1 (39)&#xD;
&#xD;
          -  Age greater than 70&#xD;
&#xD;
          -  Weight less than 10 kg&#xD;
&#xD;
          -  Any risk of pregnancy - all female patients must have an effective form of&#xD;
             contraception or be infertile due to hysterectomy, fallopian tube, surgery or&#xD;
             premature menopause.&#xD;
&#xD;
          -  HIV Infection: Patients must be HIV negative for inclusion.&#xD;
&#xD;
          -  Poor organ function as defined in the BMT Policies and Procedures Manual.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. Douglas Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>October 25, 2005</study_first_submitted>
  <study_first_submitted_qc>October 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2005</study_first_posted>
  <last_update_submitted>August 21, 2018</last_update_submitted>
  <last_update_submitted_qc>August 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>childhood acute myeloblastic leukemia without maturation (M1)</keyword>
  <keyword>adult acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>childhood acute myeloblastic leukemia with maturation (M2)</keyword>
  <keyword>adult acute promyelocytic leukemia (M3)</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>adult acute myelomonocytic leukemia (M4)</keyword>
  <keyword>childhood acute myelomonocytic leukemia (M4)</keyword>
  <keyword>adult acute monoblastic leukemia (M5a)</keyword>
  <keyword>adult acute monocytic leukemia (M5b)</keyword>
  <keyword>childhood acute monoblastic leukemia (M5a)</keyword>
  <keyword>childhood acute monocytic leukemia (M5b)</keyword>
  <keyword>adult erythroleukemia (M6a)</keyword>
  <keyword>adult pure erythroid leukemia (M6b)</keyword>
  <keyword>childhood acute erythroleukemia (M6)</keyword>
  <keyword>adult acute megakaryoblastic leukemia (M7)</keyword>
  <keyword>childhood acute megakaryocytic leukemia (M7)</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

